Zimmer (ZBH) Hits 52-Week High: What's Driving The Stock?
Zacks Investment Research | Nov 18, 2019 10:43PM ET
Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reached a new 52-week high of $146.67 on Nov 18, closing the session marginally lower at $144.99. The stock has rallied 6.2% since its third-quarter earnings announcement on Nov 5.
The company’s strong third-quarter earnings results, backed by robust segmental and global revenue growth, prompted the rally.
Let us delve deeper.
Q3 Performance
The company exited the third quarter on a strong note, with better-than-expected earnings and revenue numbers. The company witnessed year-over-year improvements in revenues in the majority of its segments as well as across Europe, Middle East and Africa (EMEA), and the Asia Pacific regions, which are encouraging.
Zimmer is upbeat about continuing the recent trend in the EMEA and the Asia Pacific region on product launches and strong customer adoptions. The company expects the trend to continue in the upcoming quarters as well.
Despite rise in the cost of products sold, the company registered gross margin improvement on solid topline performance. This also buoyed investors’ optimism.
Other Growth Drivers
Recent Approvals and Product Launches: Investors seem to be upbeat about the company as it provides some top-of-the-line products in the industry. Strong adoption of its products — including Persona Revision Knee System (which was recently launched commercially), JuggerStitch meniscal repair device, The Tether for treatment of scoliosis and ROSA ONE Spine System (recently cleared for use by the FDA) — buoys optimism.
The company’s mymobility digital health platform (developed in partnership with Apple (NASDAQ:AAPL)), and the flagship Persona Partial and Persona Cementless, which are among the major recent launches, instill optimism as well.
Partnership: Zimmer signed a multinational distribution agreement with Align (NASDAQ:ALGN) Technology, with respect to the iTero Element family of intraoral scanners. The agreement is expected to expand Zimmer’s footprint in the global digital restorative dentistry solutions market.
Execution of Growth Plans: The company progressed well, with respect to quality remediation in the third quarter. It is currently on track to complete the detailed remediation plan on the Warsaw North campus by the end of 2019. Additionally, the company is gaining from the global rollout of the Quality Begins With Me program, which is focused on driving sustainable quality culture.
Get The News You Want
Zacks Rank & Key Picks
Currently, Zimmer carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , NuVasive, Inc (NASDAQ:NUVA) and ResMed Inc (NYSE:RMD) .
Haemonetics, currently flaunting a Zacks Rank #1 (Strong Buy), has a projected long-term earnings growth rate of 13.5%. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.